20.01 0.00 (0.00%)
After hours: 4:17PM EDT
|Bid||0.00 x 1000|
|Ask||0.00 x 4000|
|Day's Range||19.30 - 20.42|
|52 Week Range||14.50 - 28.74|
|Beta (3Y Monthly)||0.47|
|PE Ratio (TTM)||454.77|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.36|
FLINT, Mich. , Oct. 16, 2018 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), will release its third-quarter 2018 operating results after market close Tuesday, Nov. 6 , with a conference call to follow ...
NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
FLINT, Mich., Sept. 27, 2018 /PRNewswire/ -- Diplomat Pharmacy, Inc. (DPLO), has opened a 75,000-square-foot facility in Chandler, Arizona, to bolster pharmacy operations and ensure business continuity. CEO and Chairman Brian Griffin said the Chandler facility — 485 N. Juniper Drive — increases Diplomat's capacity to serve more patients with greater efficiency.
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to start learning about core conceptsRead More...
The nation's largest independent provider of specialty pharmacy and infusion services will present at three upcoming investor conferences FLINT, Mich. , Aug. 30, 2018 /PRNewswire/ -- Diplomat Pharmacy, ...
Higher expenses turn solid revenue growth into a second-quarter loss for the pharmacy benefit manager and specialty pharmacy combination.
Diplomat Pharmaceuticals (DPLO) delivered earnings and revenue surprises of -26.09% and -0.33%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Flint, Michigan-based company said it had a loss of 5 cents per share. Earnings, adjusted for one-time gains and costs, came to 17 cents per share. The results did not meet Wall Street expectations. ...
2nd Quarter Revenue of $1,416 Million , an increase of 26%, Net (Loss) Income Attributable to Diplomat of $(4.0) Million compared to $3.6 Million , Adjusted EBITDA of $42.7 Million , an increase of 70% ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Diplomat Pharmacy, Inc. (NYSE: DPLO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 5:00 PM Eastern Time. ...
On Monday, Diplomat Pharmacy (NYSE: DPLO ) will release its latest earnings report. Check out Benzinga's report to understand the report's implications. Earnings and Revenue Wall Street analysts see Diplomat ...
NEW YORK, Aug. 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CVB ...
FLINT, Mich. , July 23, 2018 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), will release its second-quarter 2018 operating results after market close Monday, Aug. 6 , with a conference call to ...
Today, WallStEquities.com takes a close look at the following Generic Drugs stocks: Catalent Inc. (NYSE: CTLT), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Collegium Pharmaceutical Inc. (NASDAQ: COLL), and Diplomat Pharmacy Inc. (NYSE: DPLO). Generic pharmaceutical and medicine manufacturers develop prescription and over-the-counter drug products that are used to prevent or treat illnesses in humans or animals.
In this article I am going to calculate the intrinsic value of Diplomat Pharmacy Inc (NYSE:DPLO) by taking the foreast future cash flows of the company and discounting them backRead More...
FLINT, Mich., June 5, 2018 /PRNewswire/ -- Diplomat Pharmacy, Inc. (DPLO) ("Diplomat" or the "Company") today announced that the Compensation Committee (the "Compensation Committee") of the Board of Directors (the "Board") has made certain equity awards to new CEO Brian Griffin, effective June 4, 2018. The awards were made pursuant to the Company's previously-announced employment agreement with Mr. Griffin, and as a material inducement to his joining Diplomat as CEO and Chairman of the Board.
SAN DIEGO, CA / ACCESSWIRE / June 4, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Diplomat Pharmacy Inc (DPLO). Investors, who purchased shares of Diplomat Pharmacy Inc (DPLO) in September 2014 or earlier and continue to hold any of those NYSE: DPLO shares, have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554. On November 10, 2016, a lawsuit was filed against Diplomat Pharmacy Inc over alleged securities laws violations.
Integration of the new pharmacy benefit manager into the specialty pharmacy is proceeding well, with a new CEO to lead the way from here.
Ben Wolin, Chairman of the Board, said, "We are pleased to welcome Brian to the Diplomat team at this important time, and are confident that his dynamic skillset and significant industry experience make him ideally suited to assume the roles of CEO and Chairman. Brian is a proven healthcare executive having served in various leadership roles for many years, including at Express Scripts, Empire BlueCross BlueShield and Anthem, most recently launching its PBM organization.
FLINT, Mich., May 8, 2018 /PRNewswire/ -- Diplomat Pharmacy, Inc. (DPLO) ("Diplomat" or the "Company") today announced that the Board is in the final stages of its search process for a permanent CEO and expects to name Diplomat's next CEO by the end of this week. The Company also announced that Jeff Park has resigned voluntarily as Interim CEO, effective Friday, May 11, 2018, but will remain a director on Diplomat's Board. After Mr. Park steps down, Atul Kavthekar, CFO of Diplomat, will temporarily assume the additional responsibilities of the CEO until the appointment of the new CEO is effective.